Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and MorphoSys AG

Pharma Giants: Cost of Revenue Insights 2014-2023

__timestampBristol-Myers Squibb CompanyMorphoSys AG
Wednesday, January 1, 2014393200000077000
Thursday, January 1, 2015390900000077000
Friday, January 1, 2016494600000097000
Sunday, January 1, 2017606600000033000
Monday, January 1, 201865470000001796629
Tuesday, January 1, 2019807800000012085198
Wednesday, January 1, 2020117730000009174146
Friday, January 1, 2021994000000032200000
Saturday, January 1, 20221013700000048620000
Sunday, January 1, 20231069300000058355000
Monday, January 1, 202411949000000
ngram

Cost of Revenue Trends: Bristol-Myers Squibb vs. MorphoSys AG

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. From 2014 to 2023, Bristol-Myers Squibb Company (BMY) and MorphoSys AG (MOR) have shown distinct trajectories in their cost of revenue. Bristol-Myers Squibb, a giant in the sector, saw its cost of revenue grow by approximately 172%, from $3.9 billion in 2014 to over $10.6 billion in 2023. This reflects its expansive operations and increased production costs. In contrast, MorphoSys AG, a smaller player, experienced a staggering increase of over 75,000% in the same period, albeit from a much smaller base, highlighting its rapid growth and scaling efforts. These trends underscore the differing strategies and market positions of these companies, offering valuable insights into their operational efficiencies and market dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025